The risk factors of urinary tract infection after transurethral resection of bladder tumors.
Antimicrobial prophylaxis
Surgical site infection
Transurethral resection of bladder tumors
Urinary tract infections
Journal
World journal of urology
ISSN: 1433-8726
Titre abrégé: World J Urol
Pays: Germany
ID NLM: 8307716
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
received:
05
12
2018
accepted:
20
03
2019
pubmed:
28
3
2019
medline:
3
4
2020
entrez:
28
3
2019
Statut:
ppublish
Résumé
Few studies mention the necessity of antimicrobial prophylaxis (AMP) for transurethral resection of bladder tumor (TURBT) and the risk factors for postoperative urinary tract infections (UTIs) after TURBT. To evaluate the necessity of AMP and to detect the risk of UTIs, we examined the perioperative clinical factors. 687 patients who underwent TURBT between 2006 and 2017 at Hiroshima Prefectural Hospital were examined retrospectively. We defined the postoperative UTIs as febrile UTIs (≥ 38 °C). The AMP for the TURBT that we used was mostly cephalosporin generation 1. The association between the perioperative clinical/pathological factors and postoperative UTIs was assessed by logistic regression retrospectively. 21 patients (3.1%) suffered from postoperative UTIs, and almost all of them were successfully treated with the immediate administration of antibiotics. Univariate analysis showed that past pelvic radiotherapy (p = 0.024, odds ratio (OR) 6.00), tumor size (≥ 2cm) (p = 0.008, OR 3.38), age (≥ 75 years) (p = 0.036, OR 2.65), preoperative hospital stay (≥ 5 days) (p = 0.017, OR 3.76), asymptomatic pyuria (p = 0.038, OR 2.54) and bacteriuria (p = 0.044, OR 2.97) were all associated with postoperative UTIs. We demonstrated that AMP was effective for patients who underwent TURBT, and history of pelvic radiotherapy, high age, preoperative hospital stay and a certain tumor size were the risk factors as well as pyuria and bacteriuria of postoperative UTIs.
Identifiants
pubmed: 30915527
doi: 10.1007/s00345-019-02737-3
pii: 10.1007/s00345-019-02737-3
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2715-2719Références
J Urol. 1980 Sep;124(3):345-6
pubmed: 7001043
Infection. 1990;18 Suppl 2:S98-102
pubmed: 2286470
Int J Urol. 2004 Nov;11(11):941-7
pubmed: 15509195
Int J Urol. 2009 Jan;16(1):61-3
pubmed: 19120528
Urol Ann. 2013 Apr;5(2):61-74
pubmed: 23798859
J Urol. 2008 Apr;179(4):1379-90
pubmed: 18280509
Gynecol Oncol. 1995 Jun;57(3):380-2
pubmed: 7774842
J Urol. 1983 Jun;129(6):1123-4
pubmed: 6854784
Br J Urol. 1988 Aug;62(2):136-9
pubmed: 3044484
Urology. 1986 May;27(5):421-3
pubmed: 3518183
J Urol. 1996 Jul;156(1):146-8
pubmed: 8648777
Eur Urol. 2005 Apr;47(4):549-56
pubmed: 15774257
Urology. 1990 Jan;35(1):5-8
pubmed: 2296816
Urologia. 2015 Oct;82 Suppl 3:S2-5
pubmed: 26937514
Clin Oncol (R Coll Radiol). 1990 Jan;2(1):18-21
pubmed: 2261384
J Urol. 2005 Apr;173(4):1175-81
pubmed: 15758736
Lancet. 2013 Sep 28;382(9898):1105-12
pubmed: 24075050
Radiother Oncol. 1989 Dec;16(4):305-9
pubmed: 2616817
J Anesth. 2002;16(3):242-4
pubmed: 14517648
Am J Med. 1992 Apr 6;92(4A):114S-117S
pubmed: 1580268
Int J Urol. 2004 Jun;11(6):355-63
pubmed: 15157202
Urol Oncol. 2015 Aug;33(8):338.e19-24
pubmed: 26072111
Int J Urol. 2016 Oct;23(10):814-824
pubmed: 27531443
Infection. 1992;20 Suppl 3:S213-6; discussion S217-20, S224
pubmed: 1490747
Rev Bras Ortop. 2015 Oct 23;50(6):638-46
pubmed: 27218074
Prog Urol. 1993 Aug-Sep;3(4):577-82
pubmed: 8401618
Clin Oncol (R Coll Radiol). 1994;6(2):116-20
pubmed: 8018569